Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Vistin Pharma ASA ( (DE:VP4) ) just unveiled an announcement.
Vistin Pharma ASA plans to authorize its board to distribute an ordinary cash dividend of up to NOK 1.50 per share for the 2025 financial year, split into NOK 1 in May 2026 and up to NOK 0.50 in November 2026. The first dividend tranche of NOK 1 per share is scheduled around 29 May 2026, following approval at the 20 May 2026 annual general meeting, signaling continued cash returns to shareholders and potentially reinforcing the company’s appeal to income-focused investors.
The key dates for the May 2026 dividend include 21 May as the last day including rights, 22 May as the ex-dividend date, and 26 May as the record date, providing clarity for shareholders and market participants. Details of the planned second dividend payment in November 2026 will be announced later, indicating that Vistin Pharma is aligning its dividend policy with a structured, semi-annual payout framework that may enhance predictability and support its capital markets profile.
More about Vistin Pharma ASA
Vistin Pharma ASA is a Norwegian pharmaceutical company focused on producing active pharmaceutical ingredients and finished dosage forms. The company operates primarily in the generics segment, supplying key products to international healthcare and pharmaceutical markets.
Average Trading Volume: 18,063
Current Market Cap: NOK886.9M
Learn more about VP4 stock on TipRanks’ Stock Analysis page.